

Neumann et al

In our April 2010 issue, some references were inadvertently omitted from the article by Neumann et al, entitled *Low Value Services in Value-Based Insurance Design* (*Am J Manag Care*. 2010;16(4):280-286). The omission resulted in incorrect references being cited in **Table 1**. The corrected table and the additional references appear below. A fully corrected version of the article is available online at http://ajmc.com/issue/managed-care/2010/2010-04-vol16-n04/AJMC_10apr_Neumann_280to286.

■ **Table 1.** Selected Services With Relatively Unfavorable Cost-Effectiveness

Service	Compared With:	Cost-Effectiveness (2007 US Dollars)
Lung volume reduction surgery	Continued medical treatment	\$100,000-\$300,000 per QALY ⁴⁷
Cetuximab for the treatment of metastatic colorectal cancer after failure of chemotherapy	Active/best supportive care	\$110,000-\$410,000 per QALY ^{48,49}
Anastrozole in women with estrogen-receptor positive breast cancer	Tamoxifen	\$270,000 per QALY ⁵⁰
Transmyocardial revascularization for patients with severe angina refractory to standard medical therapy	Continued medical therapy	\$440,000 per QALY ⁵¹
Left ventricular assist devices	Optimal medical care	\$500,000-\$1.4 million per QALY ⁵²
Pemetrexed to treat non-small-cell lung cancer	Docetaxel Erlotinib and docetaxel	\$870,000 per QALY ⁵³ Increases cost and results in worse health outcomes ⁵⁴
Positron emission tomography in Alzheimer's disease	Standard examination	Increases cost and results in worse health outcomes ⁵⁵

QALY indicates quality-adjusted life-year.

Additional References

- 47. Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. *N Engl J Med*. 2003; 348(21):2092-2102.
- 48. Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. *Br J Cancer*. 2007; 96(2):206-212.
- 49. Norum J. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. *J Chemother*. 2006; 18(5):532-537.
- 50. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. *Cancer*. 2004; 101(6):1311-1322.
- 51. Campbell HE, Tait S, Buxton MJ, et al. A UK trial-based cost-utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris. *Eur J Cardiothorac Surg*. 2001; 20(2):312-318.
- 52. Gillick MR. Medicare coverage for technological innovations--time for new criteria? *N Engl J Med*. 2004; 350(21):2199-2203.
- 53. National Institute for Health and Clinical Excellence (NICE). Pemetrexed for the treatment of non-small-cell lung cancer. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Aug. 20 p. (Technology appraisal guidance; no. 124). Available at <http://www.nice.org.uk/nicemedia/live/11823/36170/36170.pdf>. Accessed May 4, 2010.
- 54. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). *Lung Cancer*. 2008; 61(3):405-415.
- 55. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. *Radiology*. 2003; 228(2):515-522.

Sankaranarayanan et al

Due to an editorial oversight in incorporating the author's corrections, an error appeared in the conclusion statement of the article by Sankaranarayanan et al, *Age and Rural Residence Effects on Accessing Colorectal Cancer Treatments* (*Am J Manag Care*. 2010;16(4):265-273). The text on p 272 of our April 2010 issue should have read, "Further investigation is needed to understand the decreased likelihood of chemotherapy among patients with colon cancer living in rural (vs micropolitan) counties and the decreased likelihood of all cancer treatment types among older patients with colon cancer and with rectal cancer." A corrected version of the article is available online at http://ajmc.com/media/pdf/AJMC_10aprBSankarana_265to273.pdf.